DRUG
Bright Minds Biosciences Inc.Closed50.71−0.65 −1.27%USD
NasdaqCM · as of Oct 14, 16:00 ET · 15m delay
Open
49.59
Prev close
51.36
Day range
49.0652.96
52-week range
47.23123.75
Volume
199.35K1.32×
Mkt cap
500.21M
P/E ttm
—
Fwd P/E
-8.79
EPS ttm
-2.05
Div yield
0.00%
Earnings
—
From 52w high
−59.02%
DRUG earnings and estimates
DRUG Next Report
Yahoo Finance · Nasdaq
Report date
Mon, Aug 17
After the close · estimated
EPS consensus
$−1.36
range −2.12 – −0.61
EPS growth vs year ago
−134.2%
year ago −0.58
Revenue consensus
$0
0.0% vs year ago
Options-implied move
—
no expiry soon after the report
Past 4 reactions
±4.7%
average move · beat 4 of 4
EPS: Actual vs Estimate
Price Reaction
close before → close after the report
Recent Reports
| Quarter ending | Reported | EPS | Estimate | Surprise | Revenue | Next session | Five sessions |
|---|---|---|---|---|---|---|---|
| Jun '26 | Aug 14, 2026 AMC | −0.24 | −1.64 | +85.34% | $0 | +4.0% | +1.3% |
| Mar '26 | May 19, 2026 AMC | −1.09 | −1.26 | +13.49% | $0 | +11.1% | +16.8% |
| Dec '25 | Feb 12, 2026 AMC | −0.97 | −1.19 | +18.14% | $0 | −3.3% | +6.1% |
| Sep '25 | Dec 23, 2025 AMC | −0.58 | −1.00 | +41.85% | $0 | +0.5% | −7.4% |
Consensus Estimates and Revisions
| Period | EPS | Low · range · high | Growth | Revenue | Growth | 30d ago | 90d ago | Up / down (30d) |
|---|---|---|---|---|---|---|---|---|
| Current quarter Sep 2026 | −1.36 | −2.12−0.61 | −134.2% | $0 | 0.0% | −1.33 −2.0% | −2.16 +37.1% | 5 / 1 |
| Next quarter Dec 2026 | −1.82 | −2.72−1.21 | −87.6% | $0 | 0.0% | −1.84 +1.0% | −2.78 +34.6% | 4 / 0 |
| Current year Sep 2026 | −3.67 | −4.47−2.85 | −106.3% | $0 | 0.0% | −3.65 −0.7% | −6.05 +39.3% | 6 / 0 |
| Next year Sep 2027 | −8.20 | −13.48−4.24 | −123.2% | $30.25M | 0.0% | −8.16 −0.4% | −12.09 +32.2% | 5 / 1 |
The change columns show how the consensus has moved since then; steady upward revisions often precede beats. Ranges place the consensus between the lowest and highest analyst estimate.
Forward EPS Forecasts
Nasdaq · Zacks consensus
Quarterly
| Fiscal period | Consensus | Low · range · high | Analysts | Up / down (4w) |
|---|---|---|---|---|
| Sep 2026 | −1.07 | −1.38−0.76 | 2 | 0 / 0 |
| Dec 2026 | −1.09 | −1.30−0.87 | 2 | 0 / 0 |
| Mar 2027 | −1.31 | −1.57−1.05 | 2 | 0 / 0 |
| Jun 2027 | −1.33 | −1.38−1.27 | 2 | 0 / 0 |
| Sep 2027 | −1.55 | −1.56−1.54 | 2 | 0 / 0 |
Fiscal years
| Fiscal period | Consensus | Low · range · high | Analysts | Up / down (4w) |
|---|---|---|---|---|
| Sep 2026 | −2.93 | −3.22−2.42 | 3 | 0 / 0 |
| Sep 2027 | −6.77 | −9.72−4.77 | 3 | 0 / 0 |
| Sep 2028 | −6.47 | −7.91−5.04 | 2 | 0 / 0 |
| Sep 2029 | −6.93 | −11.07−2.79 | 2 | 0 / 0 |
Reactions run from the last close before a report to the first close after it (an after-the-close report is measured to the next day's close). The implied move is the at-the-money straddle for the first expiry after the report, the same rule as the bot's lgf emove.